GlassScriptPhysician profile
Todd David Seamons
NPI 1821125907
$4,988.32
in general payments reported to CMS, 2019-2025
47 companies · $682 in 2025
The $682 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $752 · 2022: $1,006 · 2023: $1,224 · 2024: $1,325 · 2025: $682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,230.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,224.72 | 2021-2025 | |
| Corium, LLC | $430.03 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $324.75 | 2021-2025 | Qelbree |
| Astrazeneca Pharmaceuticals LP | $253.76 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $242.87 | 2021-2025 | |
| Axsome Therapeutics, INC. | $224.62 | 2023-2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $219.66 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Tris Pharma INC | $167.45 | 2022-2024 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $164.47 | 2021-2025 | Trintellix |
| Xeris Pharmaceuticals, INC. | $116.49 | 2021-2023 | Keveyis |
| Idorsia Pharmaceuticals US INC | $109.11 | 2022-2024 | Quviviq |
| Janssen Pharmaceuticals, INC | $107.52 | 2022-2025 | Spravato |
| Lilly USA, LLC | $100.53 | 2021-2024 | Mounjaro, Zepbound |
| Neurocrine Biosciences, INC. | $97.58 | 2023-2025 | Ingrezza |
| Abbott Laboratories | $87.60 | 2022-2025 | Freestyle Libre 3 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Seamons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.